Mental illness as a metabolic disorder, not a side effect problem
Metabolic pathways in mental illness refer to the genetically and biochemically driven processes by which the body and brain convert food into energy, regulate blood sugar and lipids, and maintain cellular function, which emerging research suggests are central to schizophrenia and bipolar disorder, not peripheral side effects. Severe mental disorders such as schizophrenia and bipolar disorder show an extensive genetic overlap with blood metabolic markers, with 1,056 shared genes involved in energy metabolism, immune function, and synapse structure. At the same time, people with psychotic disorders struggle with impaired cognition and disrupted daily living, while their standard medications are notorious for causing weight gain, high blood sugar, and metabolic syndrome. The dominant story has been that antipsychotics create metabolic damage; the new data argue the biology of these illnesses is metabolically wired from the start.
Genetics reveal a paradox in schizophrenia and bipolar disorder
The most provocative finding is that schizophrenia and bipolar disorder genetics point toward healthier metabolic profiles, even as patients develop severe metabolic illness in real life. Genetic variants that increase risk for schizophrenia and bipolar disorder are linked to lower levels of traditional cardiometabolic risk markers, the exact opposite of what is seen in major depressive disorder. Yet medical records show that all three conditions are associated with poor metabolic health, including higher rates of diabetes and cardiovascular disease. This contradiction forces an uncomfortable conclusion: environment and treatment may be pushing already vulnerable metabolic pathways into failure. Medications used for psychosis often cause weight gain and metabolic disruption. According to Dennis van der Meer, genetic data now allow researchers to “look at the shared biology without those confounders,” using large biobank datasets of more than 300,000 people.
Ketogenic diet hints that changing fuel can change symptoms
If schizophrenia and bipolar disorder are wired through metabolic pathways, food is no longer background noise—it is a therapeutic variable. A randomized study of 58 adults with schizophrenia-spectrum or bipolar I disorder tested a ketogenic diet versus usual diet over one month. The ketogenic diet contained about 70% fat, 20% protein, and 10% carbohydrates, shifting brain fuel from glucose to ketone bodies. Participants in the ketogenic group showed improved metabolic markers, including better blood sugar regulation, and maintained nutritional ketosis by objective blood tests. In an extension phase, four months of ketogenic eating were associated with enhanced cognition, reduced positive and negative schizophrenia symptoms, and less depression. The fact that a fuel switch can modify both metabolic health and psychiatric symptoms is a loud signal: metabolic pathways in mental illness are not passive bystanders but active treatment targets.
From side effects to biology: rethinking medication and monitoring
The old narrative blames medication metabolic side effects; the new evidence says those side effects are landing on already distorted biology. Individuals with severe mental disorders die 10–20 years earlier, mostly from cardiometabolic disease. When genetics suggest schizophrenia and bipolar disorder risk alleles correlate with lower cardiometabolic markers, but real-world patients still develop obesity, diabetes, and metabolic syndrome, lifestyle and treatment become the obvious suspects. Antipsychotics remain essential, but their metabolic costs demand aggressive monitoring and management, not afterthought lab tests. Metabolic syndrome—a cluster of high blood pressure, elevated fasting glucose, and other risk factors—shortens life and worsens psychiatric symptoms. Ignoring it is malpractice in slow motion. Proactive metabolic monitoring, dietary support, and physical activity should sit alongside dose adjustments and symptom checklists as baseline psychiatric care.
Toward precision psychiatry built on metabolic pathways
Genetic data show that major depression, bipolar disorder, and schizophrenia each share a different pattern of overlap with metabolic markers, with bipolar disorder sharing about 85% and schizophrenia 52% of causal variants with these metabolites. “Mental and metabolic health are connected at a biological level, but differently per disorder,” van der Meer notes. That difference should be the foundation of treatment, not a footnote. Researchers now plan to dissect diagnostic subtypes with finer metabolic profiles and to test whether specific pathways can serve as treatment targets, a direction strengthened by interest in GLP-1–based interventions for psychiatric symptoms. On the nutritional front, investigators are calling for larger, longer randomized trials of ketogenic diet psychiatric treatment to confirm its safety and effectiveness in serious mental illness. The path forward is clear: metabolic pathways in mental illness must move from side column to headline in how we design, personalize, and judge psychiatric care.
